OncoSil Medical Ltd
OSL
Company Profile
Business description
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.
Contact
7 Eden Park Drive
Level 5
Macquarie Park
SydneyNSW2113
AUST: +61 289359629
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 June 2026
Employees
2
Stocks News & Analysis
stocks
ASX reporting season wrap: CBA, JB Hi-Fi, REA and more
A round up of notable stories and reactions as ASX earnings season gathers steam.
stocks
Market overreacts to soft guidance from ASX share
Shares undervalued after they plunge following results.
stocks
CBA earnings: The only thing that puzzles us is the share price
No surprises in fiscal 2025 earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,149.10 | 46.00 | 0.51% |
| CAC 40 | 7,847.44 | 42.47 | 0.54% |
| DAX 40 | 24,330.96 | 145.37 | 0.60% |
| Dow JONES (US) | 44,816.49 | 105.78 | -0.24% |
| FTSE 100 | 9,159.68 | 5.55 | -0.06% |
| HKSE | 25,519.32 | 94.35 | -0.37% |
| NASDAQ | 21,710.03 | 3.11 | -0.01% |
| Nikkei 225 | 42,649.26 | 625.41 | -1.45% |
| NZX 50 Index | 12,834.08 | 67.54 | 0.53% |
| S&P 500 | 6,458.69 | 7.89 | -0.12% |
| S&P/ASX 200 | 8,873.80 | 46.70 | 0.53% |
| SSE Composite Index | 3,666.44 | 17.02 | -0.46% |